Trial Profile
A retrospective, single institutional experience assessing the effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Feb 2019
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record